Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists
Oncology · 2024
DOI: 10.1159/000535855 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Udit Nindra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Practice Patterns, Physicians'. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Introduction
Local Australian guidelines for the optimal management of stage III unresectable non-small cell lung cancer (NSCLC) are lacking. The American Society of Clinical Oncology (ASCO) guidelines recommend consolidation durvalumab for all patients with unresectable stage III NSCLC, irrespective of their PD-L1 expression or driver mutation status. The European Society of Medical Oncology (ESMO) differs, with consolidation durvalumab only recommended in those patients whose tumours express PD-L1.
Methods
Due to differing global guidelines, we conducted an Australia and New Zealand wide survey of medical oncologists specialising in thoracic cancer to determine the variations in patterns of prescribing durvalumab in stage III unresectable NSCLC. This survey was done electronically and sponsored by the Thoracic Oncology Group of Australia (TOGA).
Results
Thirty-two medical oncologists completed the survey. In patients with EGFR-mutated stage III unresectable NSCLC, 6% of respondents stated that they prescribed durvalumab for all patients, while an additional 6% strongly recommended treatment. Forty-four percent suggested little benefit of consolidation durvalumab in this cohort, with an additional 19% advocating for observation only. In patients with PD-L1 negative (0%) stage III unresectable NSCLC, 13% of respondents prescribed durvalumab for all patients, while an additional 56% strongly recommended treatment. Interestingly, 18%, 10%, and 10% of prescribers discussed self-funded oral tyrosine kinase inhibitor therapy in patients with EGFR, ALK, or ROS-1-mutated NSCLC respectively as a substitute for consolidation durvalumab.
Conclusion
Overall, the clinical practice of Australian and New Zealand Medical Oncologists is variable, but remains consistent with either the ASCO or ESMO guidelines. Local practice guidelines are required to ensure consistency in prescribing patterns across Australia, as well as providing evidence for self-funded treatments outside standard of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
- Department of Medical Oncology, Nepean Hospital, Nepean, New South Wales, Australia.
- Department of Medical Oncology, Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia.
- Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
- Department of Medical Oncology, Sydney, New South Wales, Australia.
Zitieren
APA
Nindra, U., Bray, V., Karikios, D., Shafiei, M., Subramaniam, S., Ding, P., Kao, S., & Pal, A. (2024). Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists. Oncology. https://doi.org/10.1159/000535855
Vancouver
Nindra U, Bray V, Karikios D, Shafiei M, Subramaniam S, Ding P, et al. Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists. Oncology. 2024. doi:10.1159/000535855
BibTeX
@article{Nindra2024,
author = {Nindra, Udit and Bray, Victoria and Karikios, Deme and Shafiei, Mohsen and Subramaniam, Shalini and Ding, Pei and Kao, Steven and Pal, Abhijit},
title = {Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists},
journal = {Oncology},
year = {2024},
doi = {10.1159/000535855}
}
EUVIMED